Clinical Trials Logo

Adjuvant clinical trials

View clinical trials related to Adjuvant.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00525642 Active, not recruiting - Breast Neoplasms Clinical Trials

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

Start date: June 2003
Phase: Phase 2/Phase 3
Study type: Interventional

Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer. Also in this group of patients, data from BCIRG-001 trial had shown that six cycles of adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) is superior to standard FAC (5-FU, doxorubicin and cyclophosphamide ) combination in terms of both disease free and overall survival, while associated with a higher rate of febrile neutropenia. Then question arose whether it is better to use docetaxel and anthracycline in combination or sequence.